Charcot-Marie-Tooth disease type 4H is a rare genetic neuropathy that affects the peripheral nerves. People with Charcot-Marie-Tooth disease type 4H often develop slowly progressive weakness and wasting in the lower legs and feet, and later in the hands. Walking can become harder over time, and high arches, hammertoes, numbness, and reduced reflexes are common features a doctor may see. Symptoms usually begin in childhood or the teen years and last lifelong, and not everyone will have the same experience. Treatment focuses on supportive care like physical and occupational therapy, braces or custom shoes, pain control, and regular monitoring, and most people have a near-normal life span.
Overview
Charcot-marie-tooth disease type 4hSymptoms
Early symptoms of Charcot‑Marie‑Tooth disease type 4H often include ankle weakness, tripping, and foot deformities like high arches or hammertoes. Many develop foot drop, numbness or tingling, poor balance, and reduced reflexes. Hand weakness and scoliosis can appear over time.
Outlook and prognosis
Most people with Charcot‑Marie‑Tooth disease type 4H notice slowly progressive leg and hand weakness, foot shape changes, and balance issues starting in childhood or adolescence. Daily function can remain stable for years with targeted therapy and braces. Regular neurologic and orthopedic care helps prevent falls, protect joints, and support independence.
Causes and risk factors
The genetic causes of Charcot-Marie-Tooth disease type 4H are autosomal recessive changes, typically when both parents are carriers. Main risk is family history; carrier parents—especially if related—raise risk. Environment and lifestyle don’t cause it, though general health may affect complications.
Genetic influences
Genetics are central in Charcot-Marie-Tooth disease type 4H. It’s caused by inherited gene changes, usually autosomal recessive, meaning two nonworking copies are needed. Specific variants influence age at onset, severity, progression, and sometimes responsiveness to supportive therapies.
Diagnosis
Diagnosis of Charcot-Marie-Tooth disease type 4H starts with clinical features on exam, supported by nerve conduction studies. Genetic diagnosis of Charcot-Marie-Tooth disease type 4H is confirmed with targeted genetic tests; nerve biopsy or imaging is reserved for unclear cases.
Treatment and drugs
Treatment for Charcot‑Marie‑Tooth disease type 4H focuses on preserving strength, balance, and independence. Care often includes physiotherapy, ankle‑foot orthoses, pain control, and tailored exercise; some may benefit from occupational therapy and orthopedic surgery. Regular follow‑up with neuromuscular specialists helps adjust supports over time.
Symptoms
Many families first notice changes in the feet and legs—unsteady walking, frequent tripping, or feet that look higher arched than expected. Parents may notice early features of Charcot-marie-tooth disease type 4h, like delayed walking or toe-walking. Loved ones often notice the changes first. Hands and balance can also be affected, and many tire more easily during longer walks.
Many children walk later than peers and may toe-walk or trip often. This reflects early involvement of the nerves serving the legs.
High arches and hammertoes are common and can make finding comfortable shoes hard. In Charcot-marie-tooth disease type 4h, these changes often appear in childhood.
Lifting the front of the foot can be difficult, leading to a slapping or high-stepping gait. Foot drop is a common sign in Charcot-marie-tooth disease type 4h.
Unsteady footing is more noticeable on uneven ground or in the dark. This can lead to falls or needing to hold handrails on stairs.
How people usually first notice Charcot-marie-tooth disease type 4h?
Many people first notice Charcot-Marie-Tooth disease type 4H in childhood when a child seems clumsier than peers, trips often, or struggles to keep up in sports, sometimes with unusually high foot arches or hammertoes that make shoe-fitting hard. Parents or clinicians may pick up early weakness in the lower legs and hands, decreased reflexes, or reduced sensation in the feet, and “steppage” walking due to foot drop; over time, calf muscles can look thinner. These early changes prompt evaluation by a neurologist, nerve testing, and genetic testing, which together confirm the diagnosis and explain the first signs of Charcot-Marie-Tooth disease type 4H.
Types of Charcot-marie-tooth disease type 4h
Charcot-Marie-Tooth disease type 4H (CMT4H) is a rare, inherited neuropathy caused by pathogenic changes in the FGD4 gene. It’s considered an early-onset, demyelinating form, but doctors recognize variation in when symptoms begin and how quickly they progress. People may notice different sets of symptoms depending on their situation. When discussing types of CMT4H, the best way is to look at recognized clinical variants based on age at onset and progression, since no separate gene-based subtypes beyond FGD4 are widely accepted; this helps clarify the practical “types of CMT4H” you might hear about in clinics.
Infant-onset variant
Symptoms start in late infancy or early toddler years with delayed walking and frequent falls. Weakness and low muscle tone in the legs come first, with foot deformities (like high arches) developing early. Sensory loss is often mild at first but becomes more apparent over time.
Childhood-onset variant
First signs appear in early school years with clumsiness, tripping, and difficulty running. Foot changes and lower-leg wasting emerge gradually, and hand weakness may follow later. Progression is steady but varies from child to child.
Adolescent-onset variant
Subtle symptoms begin around puberty with ankle instability and trouble with sports. Hand grip weakness and fine-motor challenges may surface during secondary school. Progression tends to be slower than earlier-onset forms.
Severe early-progressive
Marked weakness and rapid functional decline occur in the first years of life. Early need for bracing or mobility aids is common, and scoliosis may be identified during childhood checkups. Sensory symptoms and nerve conduction studies show clear demyelination early.
Milder slow-progressive
Symptoms start later and advance gradually, sometimes not requiring braces until adolescence. People often manage daily activities with minimal support for years. Even within this variant, intensity can range from mild to moderate.
What genetics can tell you about symptoms
In CMT4H, mutations in FGD4 disrupt myelin, the nerve insulation, leading to early-onset foot drop, high arches, weak ankles and hands, numbness, and slow reflexes. These changes slow nerve signals, so walking, balance, and fine hand tasks become harder over time.
Causes and risk factors
The root cause is a change in the FGD4 gene, usually inherited from both parents, and rarely from a new change. Main risk factors for Charcot-Marie-Tooth disease type 4H include having two carrier parents or a family history. Doctors distinguish between risk factors you can change and those you can’t. Lifestyle and environment do not cause it, but medicines that can harm nerves, heavy alcohol use, or poorly controlled diabetes can make symptoms worse. Parents who are related or come from a community with shared ancestry face a higher chance of having a child with two gene changes.
Environmental and biological risk factors
Here’s what is known about environmental and biological risks for Charcot-Marie-Tooth disease type 4H (CMT4H). So far, no body- or environment-based factor has been shown to clearly raise the chance of it occurring. Doctors often group risks into internal (biological) and external (environmental). These exposures also haven’t been shown to change early symptoms of Charcot-Marie-Tooth disease type 4H.
Older maternal age is linked to some conditions, but it has not been shown to increase the chance of CMT4H. Current evidence suggests the likelihood of CMT4H is not tied to the mother’s age.
While older paternal age can affect some health risks, a clear link to CMT4H has not been shown. The chance of CMT4H does not appear to rise with the father’s age.
Health issues during pregnancy, including diabetes or thyroid disease, are not known to raise the chance of CMT4H. Monitoring remains important for general fetal health.
Infections during pregnancy have not been shown to cause CMT4H. Standard prenatal care to prevent and treat infections remains important for overall outcomes.
Genetic risk factors
Charcot-Marie-Tooth disease type 4H most often stems from changes in a single gene, FGD4, that need to be inherited from both parents. Some risk factors are inherited through our genes. When both parents carry one FGD4 change, each child has a 25% (1 in 4) chance of having the condition. Because early symptoms of Charcot-Marie-Tooth disease type 4H often begin in childhood, families with known carrier status sometimes consider genetic counseling.
FGD4 variants: Disease-causing changes in the FGD4 gene are the direct genetic cause of CMT4H. These changes can impair the nerve insulation (myelin) made by Schwann cells.
Autosomal recessive: A child must inherit two non-working FGD4 copies—one from each parent—to develop the condition. If both parents are carriers, each pregnancy has a 25% (1 in 4) chance.
Carrier parents: People with a single FGD4 change usually have no symptoms. When two carriers have children together, the chance of the condition in each child is increased. Partner testing can clarify the likelihood for a future pregnancy.
Family history: Having a sibling or relative with this condition signals a higher chance that other family members carry the same FGD4 change. Testing an affected relative first often makes family screening more accurate.
Related parents: Parents who are blood relatives are more likely to share the same rare FGD4 variant. This raises the chance that a child will inherit two copies and develop Charcot-Marie-Tooth disease type 4H.
Founder variants: In some families or communities, one FGD4 change is more common because of a shared ancestor. This can make cases cluster within that group.
Variant type matters: Different FGD4 changes can leave more or less protein function. This can shape how early the condition starts and how severe nerve problems become.
High penetrance: When two disease-causing FGD4 variants are present, signs of CMT4H usually appear. Carriers with one variant typically remain unaffected.
Lifestyle risk factors
Lifestyle habits do not cause Charcot-marie-tooth disease type 4h, but they can shape day‑to‑day function, symptoms, and complications. Choices around movement, footwear, and self‑care can influence weakness, balance, pain, and skin integrity. Targeted routines can help you preserve mobility and reduce injury risk. Understanding how lifestyle affects Charcot-marie-tooth disease type 4h helps you focus on changes that matter most.
Regular low‑impact exercise (walking, cycling, swimming) can help maintain strength and joint range in CMT4H. Supervised balance and gait training may reduce falls and improve efficiency when nerves are weakened.
High‑resistance or repetitive loading of weak distal muscles can trigger overuse injuries and prolonged fatigue in CMT4H. Pacing, rest breaks, and symptom‑guided training help protect fragile ankles and hands.
Excess body weight increases stress on weak ankles and cavovarus feet in CMT4H, worsening pain and deformity. Modest weight loss can improve stability, brace fit, and walking endurance.
Supportive shoes and prescribed AFOs improve toe clearance, ankle control, and energy use in CMT4H. Consistent use lowers risks of sprains, trips, and skin breakdown.
Risk prevention
Charcot-Marie-Tooth disease type 4H is genetic, so we can’t prevent the condition itself, but we can lower the chance of complications and slow functional decline. The focus is on protecting nerves and muscles, keeping balance and mobility, and catching problems early before they limit daily life. Prevention works best when combined with regular check-ups. Knowing early symptoms of Charcot-Marie-Tooth disease type 4H can also guide timely care and support.
A genetics visit can clarify inheritance, carrier risks, and options for family planning. This can include carrier testing for relatives and discussion of prenatal or preimplantation options.
Noticing early symptoms of Charcot-Marie-Tooth disease type 4H—like frequent tripping, foot weakness, or trouble running—allows earlier supports. Early referral to neuromuscular and orthopedic teams can reduce long-term complications.
Low‑impact strength, balance, and flexibility work helps maintain function without overstraining weak nerves. A physical therapist can tailor a plan to CMT4H to reduce falls and joint stiffness.
Ankle‑foot orthoses and custom shoe inserts can improve foot drop and stability. Better alignment reduces falls and protects joints over time.
Transmission
Charcot-Marie-Tooth disease type 4H is a genetic condition passed down in an autosomal recessive pattern: a child needs two changed copies of the gene, one from each parent, to develop the condition. Parents are usually healthy carriers; when both carry the change, each pregnancy has a 25% chance of a child with Charcot-Marie-Tooth disease type 4H, a 50% chance of a carrier, and a 25% chance of neither. New, first-time (de novo) changes can happen but are uncommon, and most cases run in families. There is no person-to-person spread—genetic transmission of Charcot-Marie-Tooth disease type 4H happens only from parents to children.
When to test your genes
Consider genetic testing if you have progressive distal weakness, high arches or hammer toes, reduced sensation, or a family history of Charcot‑Marie‑Tooth disease. Test earlier if symptoms start in childhood or you’re planning a family, since results guide prognosis, surveillance, and reproductive options. A confirmed CMT4H diagnosis can tailor therapy, physical therapy plans, and supportive devices.
Diagnosis
For many, the first step comes when everyday activities start feeling harder—tripping more often, shoes fitting differently, or hands tiring with buttons. Getting a diagnosis is often a turning point toward answers and support. With Charcot-marie-tooth disease type 4h, doctors look at recognizable nerve and muscle changes and then confirm the cause with specific tests. The genetic diagnosis of Charcot-marie-tooth disease type 4h often combines a careful exam, nerve studies, and DNA testing to pinpoint the exact subtype.
Providers look for patterns like weakness in the feet and hands, high arches or flat feet, balance issues, and reduced reflexes. These clinical features help distinguish inherited neuropathy from other causes and guide which tests come next.
A detailed family and health history can help clarify whether symptoms run in families or suggest a recessive pattern. This context supports the choice of genetic tests and helps identify who else might benefit from evaluation.
Doctors measure how fast signals travel along nerves to see if there is demyelination, a common pattern in this condition. Marked slowing supports a hereditary neuropathy and helps separate it from nerve damage due to other conditions.
Panels that include the FGD4 gene or single-gene testing can confirm the exact subtype and provide a definitive diagnosis. Genetic testing may be offered to clarify risk or guide treatment.
Stages of Charcot-marie-tooth disease type 4h
Charcot-marie-tooth disease type 4h does not have defined progression stages. Symptoms and abilities can change slowly over years, and the pace varies between people, so it’s tracked by function rather than set “stage” labels. Different tests may be suggested to help confirm the diagnosis and follow changes over time, including a neurological exam, nerve and muscle testing, and genetic testing; early symptoms of Charcot-marie-tooth disease type 4h may include frequent tripping, ankle weakness, or foot shape changes. Doctors also monitor walking, hand strength, and spine alignment over time to guide care and support.
Outlook and prognosis
Daily routines often adapt as Charcot-Marie-Tooth disease type 4H (CMT4H) progresses—walking longer distances may take more effort, and tasks that rely on fine hand movements can become slower. The outlook is not the same for everyone, but the condition usually leads to gradually increasing weakness and sensory loss in the lower legs and feet first, then the hands. Many people find that symptoms move forward slowly over years, with periods that feel fairly stable. Doctors call this the prognosis—a medical word for likely outcomes.
Over time, most people with CMT4H need mobility support, such as ankle–foot braces, custom footwear, or a cane; a smaller group may eventually use a wheelchair for longer trips. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Falls, foot ulcers, and scoliosis are the problems that most often affect day-to-day life, but early symptoms of Charcot-Marie-Tooth disease type 4H can be eased with physical therapy, balance training, and regular foot care. Life span is generally near normal; serious complications are uncommon when respiratory function and spine health are monitored.
Looking at the long-term picture can be helpful. With ongoing care, many people maintain independence in self-care, work, and relationships, even if they adapt how they do certain activities. Talk with your doctor about what your personal outlook might look like, including how fast your symptoms seem to be changing and which supports could help now versus later. Genetic testing can sometimes provide more insight into prognosis, especially for families planning for the future.
Long-term effects
Charcot-marie-tooth disease type 4h usually unfolds slowly over years, with changes that tend to center on the feet, legs, and hands. Long-term effects vary widely, but many start in childhood and build gradually. Early symptoms of Charcot-marie-tooth disease type 4h often include clumsiness, frequent trips, or trouble keeping up in sports. Many continue school, work, and family life with practical adjustments.
Weakness typically begins in the lower legs and feet, then may involve the hands over time. This can make lifting the front of the foot, climbing stairs, or gripping small objects harder.
High arches and curled toes can gradually develop and become more pronounced. These changes may shift how the foot bears weight and make shoes fit differently.
A steppage or unsteady gait often emerges as muscles weaken. Over the years, some people with Charcot-marie-tooth disease type 4h may need braces or a wheelchair for longer distances.
Nerve changes in the legs and feet reduce position sense, which can throw off balance. Falls or near-falls can become more frequent, especially on uneven ground or in the dark.
How is it to live with Charcot-marie-tooth disease type 4h?
Living with Charcot–Marie–Tooth disease type 4H often means planning your day around energy, balance, and hand strength, since walking long distances, climbing stairs, or tasks like buttoning shirts and typing can take extra time and focus. Many notice foot drop, frequent tripping, or fatigue by late afternoon, so braces, supportive shoes, and scheduled rest breaks become practical tools rather than signs of limitation. Family, friends, and coworkers may need to adjust expectations—offering rides, allowing flexible schedules, or choosing accessible activities—while respecting the person’s independence and pace. With physical therapy, adaptive devices, and clear communication, daily life can stay active and connected, even if the route is a bit more deliberate.
Treatment and drugs
Treatment for Charcot‑Marie‑Tooth disease type 4H focuses on easing symptoms, protecting function, and maintaining independence over time. There’s no cure yet, so care usually centers on physical therapy to keep muscles flexible and strong, ankle–foot orthoses or custom shoes to improve balance and prevent trips, and occupational therapy for hand weakness and everyday tasks. Doctors sometimes recommend a combination of lifestyle changes and drugs, such as pain relievers for nerve pain or cramps, and treatment for scoliosis if it develops; surgery may be considered for severe foot deformities or significant curvature of the spine. Alongside medical treatment, lifestyle choices play a role, including regular low‑impact exercise, fall‑prevention strategies at home, and skin and foot care to avoid sores or infections. Not every treatment works the same way for every person, so regular check‑ins with a neuromuscular specialist help fine‑tune supports as needs change.
Non-drug treatment
Daily life with Charcot-Marie-Tooth disease type 4H often revolves around keeping strength, balance, and independence for as long as possible. Non-drug treatments often lay the foundation for staying mobile, protecting joints, and adapting tasks at home and work. Starting therapy soon after early symptoms of Charcot-Marie-Tooth disease type 4H appear—like tripping, foot drop, or hand clumsiness—may slow loss of function. Plans are tailored, since symptoms can vary by age and severity.
Targeted exercises maintain strength and protect joints. A therapist designs gentle, regular routines that fit your energy level.
Techniques and tools help with daily tasks like dressing, cooking, and typing. Training can reduce strain on weak hands and ankles.
Light braces support foot drop and improve walking safety. They can reduce tripping and help you walk longer with less fatigue.
Supportive shoes and insoles improve stability and pressure distribution. This can lower the risk of calluses and skin breakdown in numb areas.
Your genes may have an impact on how drugs work for you
Medications used in Charcot‑Marie‑Tooth disease type 4H can work differently from one person to another because variants in genes that process drugs affect absorption, breakdown, and side‑effects. Pharmacogenetic testing may guide safer dosing, pain control choices, and minimize nerve‑toxic risks.
Pharmacological treatments
Living with Charcot-Marie-Tooth disease type 4H often means managing nerve-related pain, muscle cramps, and aches from joint strain. Neuropathic foot and leg pain may appear early, sometimes before other early symptoms of Charcot-Marie-Tooth disease type 4H are recognized. Medicines aim to ease symptoms so daily activities feel more doable; there is no approved treatment that changes the underlying condition yet. Not everyone responds to the same medication in the same way.
Often used for burning, tingling nerve pain in the feet and legs. Dosing may be increased or lowered gradually to find the lowest effective dose with manageable side effects.
Similar to gabapentin, it can reduce shooting or electric-shock–type pain. Some feel less pain and better sleep, though dizziness and swelling can occur.
This serotonin-norepinephrine reuptake inhibitor (SNRI) helps neuropathic pain and can also support mood. Nausea or dry mouth may appear early and often improve over time.
Low-dose amitriptyline or nortriptyline may ease nighttime neuropathic pain. Sleepiness and dry mouth are common, so bedtime dosing is typical.
Genetic influences
This condition is most often linked to changes in a single gene called FGD4, which helps the nerve-supporting cells build and maintain the protective myelin around nerves. A “carrier” means you hold the gene change but may not show symptoms. Charcot-marie-tooth disease type 4h follows an autosomal recessive pattern: a child needs two changed copies—one from each parent—to develop it, while parents with just one copy typically stay well. If both parents are carriers, each pregnancy has a 25% (1 in 4) chance of an affected child, a 50% (1 in 2) chance of a carrier child, and a 25% chance of a child without the gene change. In families with two FGD4 changes, early symptoms of Charcot-marie-tooth disease type 4h often begin in childhood and may progress over time, yet severity can differ even among siblings. Genetic testing can confirm the specific gene change and help clarify risks for relatives and future pregnancies.
Is Charcot-marie-tooth disease type 4h genetic?
Genetics are central in Charcot-Marie-Tooth disease type 4H. It’s caused by inherited gene changes, usually autosomal recessive, meaning two nonworking copies are needed. Specific variants influence age at onset, severity, progression, and sometimes responsiveness to supportive therapies.
Pharmacogenetics—how genetics influence drug effects
For Charcot‑Marie‑Tooth disease type 4H, your inherited nerve condition shapes which medicines doctors choose, even though it usually doesn’t change how your liver breaks them down. Because the nerves are already vulnerable, drugs known to damage nerves—such as the chemotherapy vincristine and some antibiotics linked to neuropathy—are often avoided when safer alternatives exist. Pain and muscle symptoms are commonly managed with nerve‑pain medicines or low‑dose antidepressants; how well these work and what side effects you feel can vary from person to person. Genetic testing can sometimes identify how your body handles certain pain medicines, like codeine, tramadol, or tricyclic antidepressants, which can guide dosing or help pick a different option. For example, some people do not convert codeine or tramadol into their active form and get little pain relief, while others clear certain antidepressants quickly and may need a different dose. In Charcot‑Marie‑Tooth disease type 4H, these pharmacogenetic insights are used alongside your symptoms, kidney function, and other medicines to tailor medications used in Charcot‑Marie‑Tooth disease type 4H and avoid drugs that could worsen neuropathy.
Interactions with other conditions
People living with Charcot-Marie-Tooth disease type 4H often find that other health issues can change how their nerve symptoms feel day to day. A condition may “exacerbate” (make worse) symptoms of another. Diabetes or prediabetes, for example, can intensify numbness and tingling, slow wound healing in the feet, and raise the risk of ulcers, which can complicate walking and balance. Low thyroid levels, vitamin B12 deficiency, heavy alcohol use, and kidney disease can also aggravate nerve pain or weakness, sometimes masking early symptoms of Charcot-Marie-Tooth disease type 4H. Some medications are nerve‑toxic, so it’s important to review treatments that might worsen neuropathy—this includes certain chemotherapy drugs such as vincristine and, less commonly, other medicines that affect the nerves. If scoliosis or breathing muscle weakness is present, lung infections or sleep apnea can make fatigue and shortness of breath more noticeable, so coordinated care between neurology, orthopedics, and respiratory teams can help keep you steady.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described families in which several relatives gradually lost strength in their lower legs and feet, then later in their hands. A grandparent remembered high arches and frequent ankle sprains; a parent recalled tripping in school sports; a teen noticed fine hand tasks getting harder. These shared stories later helped doctors recognize inherited nerve conditions that affect movement and sensation.
From early theories to modern research, the story of Charcot-Marie-Tooth disease type 4H (often shortened to CMT4H) has unfolded step by step. The broader condition, Charcot-Marie-Tooth disease, was named in the late 1800s, when physicians connected progressive weakness and muscle wasting to problems in the peripheral nerves. At first, everything was grouped together under one label. Over time, descriptions became more precise as doctors noticed that some patterns ran in families where both parents were carriers and more than one child was affected—an autosomal recessive pattern—suggesting a distinct subtype.
With each decade, advances in nerve testing and later in genetics revealed that not all CMT was the same. Researchers found that some types involved damage to the nerve’s insulating layer (myelin), while others primarily affected the nerve fiber itself. CMT4H was first described as one of the demyelinating, recessive forms, often appearing in childhood with delayed walking, frequent falls, and a “steppage” gait. Early reports came from clustered families, then from communities where carrier rates were a bit higher, helping clinicians recognize the pattern across different backgrounds.
In recent decades, awareness has grown that CMT4H has its own fingerprint: childhood onset, slowly progressive leg and later hand weakness, absent reflexes on exam, and changes on nerve conduction studies that point to myelin involvement. As genetic tools improved, scientists linked CMT4H to changes in a gene that helps nerve cells maintain healthy myelin. This shift—from describing symptoms to pinpointing a gene—clarified diagnosis, allowed more accurate family counseling, and set the stage for research into targeted therapies.
Despite evolving definitions, the day-to-day experience for many living with CMT4H has remained consistent: bracing for foot drop, finding shoes that fit high arches, and adapting school or work tasks as hand strength changes. Looking back helps explain why the name is specific: it honors the broader CMT history while marking a subtype with a distinct cause and pattern. Today, the history of CMT4H is still being written, as registries, imaging, and genetic studies refine our understanding and guide future care.